HER2阳性乳腺癌脑转移患者接受曲妥珠单抗美坦新(T-DM1)联合脑立体定向放射外科治疗后的放射性坏死风险
回顾性分析韩国和意大利七家三级医疗中心2012至2022年间103例接受脑立体定向放射外科(SRS)和HER2靶向治疗的HER2阳性乳腺癌脑转移患者,共535次治疗。T-DM1暴露(+)组在患者水平和治疗水平分析中均与总体放射性坏死及症状性放射性坏死风险升高相关(患者水平HR 2.71和HR 4.34,治疗水平HR 3.13和HR 10.4)。T-DM1暴露(+)且既往全脑放疗史者放射性坏死发生率更高,作者认为需进一步研究T-DM1与SRS的最佳顺序和间隔。
要点
- T-DM1暴露(+)组患者水平总体放射性坏死风险升高(HR 2.71,p=0.020)。
- T-DM1暴露(+)组患者水平症状性放射性坏死风险升高(HR 4.34,p=0.030)。
- T-DM1暴露(+)且既往全脑放疗史者放射性坏死发生率更高。
核心结论
- 接受T-DM1联合脑SRS的患者观察到放射性坏死风险升高,需进一步研究以更好地理解T-DM1与SRS给药的最佳顺序和间隔。
研究设计与样本
- 回顾性分析2012年至2022年间韩国和意大利七家三级医疗中心诊断为脑转移并接受SRS和HER2靶向治疗的HER2阳性乳腺癌患者,共103例患者、535次治疗。
- T-DM1暴露(+)定义为在SRS前或后1年内接受T-DM1;T-DM1暴露(-)组为接受其他HER2靶向药物或在SRS前或后超过1年接受T-DM1。
- 症状性放射性坏死定义为常见不良事件评价标准(CTCAE)2级或以上。
- 中位随访时间为15.5个月(范围1.1-101.9)。
主要发现
- 患者水平多因素分析显示,T-DM1暴露(+)组总体放射性坏死风险升高(HR 2.71,p=0.020)。
- 患者水平分析显示,T-DM1暴露(+)组症状性放射性坏死风险高于T-DM1暴露(-)组(HR 4.34,p=0.030)。
- 治疗水平多因素分析显示,T-DM1暴露(+)与总体放射性坏死(HR 3.13,p=0.036)和症状性放射性坏死(HR 10.4,p=0.013)发生率较高相关。
- T-DM1暴露(+)且既往有全脑放疗史者放射性坏死发生率更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the potential relationship between trastuzumab emtansine (T-DM1) treatment and radionecrosis induced by brain stereotactic radiosurgery (SRS) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. MATERIALS AND METHODS: Patients with HER2-positive breast cancer who were diagnosed with brain metastasis and received both SRS and HER2-targeted agents between 2012 and 2022 were retrospectively analyzed. Patients who received T-DM1 within 1 year (either before or after) of SRS were considered as 'T-DM1 exposure (+)'. T-DM1 exposure (-) group had other HER2-targeted agents or received T-DM1 more than 1 year before or after SRS. Symptomatic radionecrosis was defined as Common Terminology Criteria for Adverse Events grade 2 or greater. RESULTS: A total of 103 patients with 535 treatment sessions were included from seven tertiary medical centers in Korea and Italy. The median follow-up duration was 15.5 months (range 1.1-101.9). By per-patient analysis, T-DM1 exposure (+) group had an increased risk of overall radionecrosis after multivariate analysis (HR 2.71, p = 0.020). Additionally, T-DM1 exposure (+) group was associated with a higher risk of symptomatic radionecrosis compared to T-DM1 exposure (-) patients (HR 4.34, p = 0.030). In per-treatment analysis, T-DM1 exposure (+) was linked to higher incidences of overall (HR 3.13, p = 0.036) and symptomatic radionecrosis (HR 10.4, p = 0.013) after multivariate analysis. A higher prevalence of radionecrosis was observed with T-DM1 exposure (+) and a previous history of whole brain radiotherapy. CONCLUSION: An increased risk of radionecrosis was observed in patients receiving T-DM1 with brain SRS. Further research is needed to better understand the optimal sequence and interval for administering T-DM1 and SRS.
引用
- Chun SJ, Kim K, Kim YB, et al. Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery. Radiother Oncol. 2024. PMID: 39067706. doi:10.1016/j.radonc.2024.110461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。